Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research, and Exact Sciences, a leading provider of cancer screening and diagnostic tests, today ...

Introduction to Newborn Screening InstrumentsNewborn screening is a critical medical process that involves testing newborns for certain genetic, metabolic, and congenital conditions. The objective is ...

This year’s World Cancer Day theme, ‘United by Unique,’ emphasizes a people-centred approach to cancer care, encouraging us ...

North America in vitro diagnostics (IVD) market is projected to grow by 5.6% annually in the forecast period and reach $ 54,000.3 million by 2031. The North America In Vitro Diagn ...

Global in vitro diagnostics (IVD) market will reach $148,393.3 million by 2031, growing by 6.3% annually over 2021-2031. The global in vitro diagnostics (IVD) market encompasses a wide range of ...

Earlier today, Munich Re published the latest chapter in its Life Science Report series, delving into ‘Improving Cancer ...

In a retrospective study of 265 patients with drug-resistant solid organ cancers, ‘Exacta AI’ provided at least seven therapy ...

Bladder cancer often begins with subtle symptoms that are easy to overlook. The most common early sign is blood in the urine, a condition known as hematuria. In many cases, the blood may not always be ...